Healthcare & Insurance
AB Science announces that confirmatory Phase 3 study AB12005 with masitinib in first line pancreatic cancer with pain was successful
Paris, December 4, 2020, 8.30am AB Science announces that confirmatory Phase 3 study AB12005 with masitinibin first line pancreatic cancer with pain was successful and reached its primaryobjective to show statistically significant increase in survival AB Science SA (Euronext - FR0010557264 - AB)
Friday, December 04, 2020
Nicox Raises €15 million in Private Placement
Press Release Nicox Raises €15 million in Private Placement Strengthens financial position in advance of upcoming key value inflection points Two clinical readouts in Q4 2021 – Mont Blanc Phase 3 for NCX 470 and Mississippi Phase 2b for NCX 4251Long-term shareholder HBM Healthcare
Friday, December 04, 2020
Nicox Raises €15 million in Private Placement
Press Release Nicox Raises €15 million in Private Placement Strengthens financial position in advance of upcoming key value inflection points Two clinical readouts in Q4 2021 – Mont Blanc Phase 3 for NCX 470 and Mississippi Phase 2b for NCX 4251Long-term shareholder HBM Healthcare
Friday, December 04, 2020
Sigilon Therapeutics Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the pricing of its upsized initial public offering of 7,000,000
Friday, December 04, 2020
BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
—Significant and sustained reduction in HAE attacks— —Oral, once-daily prophylactic option enables HAE patients to reduce burden of therapy1 — —ORLADEYO approved for adult and pediatric patients 12 years and older— RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2020 (GLOBE NEWSWIRE) --
Friday, December 04, 2020
Cambium Networks Corporation Announces Pricing of Secondary Offering
ROLLING MEADOWS, Ill., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Cambium Networks Corporation (Nasdaq: CMBM) (“Cambium”), a provider of wireless networking infrastructure solutions, today announced the pricing of an underwritten secondary public offering of 2,500,000 ordinary shares to be sold by
Friday, December 04, 2020
Afya Limited Announces Third Quarter and Nine Months 2020 Financial Results
Tracking in Line to Meet 2H20 GuidanceExpands Digital Health Product Offering with Three Strategic Acquisitions NOVA LIMA, Brazil and MINAS GERAIS, Brazil, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Afya Limited (Nasdaq: AFYA) (“Afya” or the “Company”), the leading medical education group in
Friday, December 04, 2020
ERYTECH Announces Conference Webcast to Discuss Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia to be Presented at the American
Webcast scheduled for Monday, December 7 at 4:00 pm CET/10:00 am ETLYON, France and CAMBRIDGE, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug
Thursday, December 03, 2020
CooperCompanies Announces Fourth Quarter and Full Year 2020 Results
SAN RAMON, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO) today announced financial results for its fiscal fourth quarter and full year ended October 31, 2020. Fourth quarter revenue decreased 1% year-over-year to $681.6 million. CooperVision (CVI) revenue down 1% to
Thursday, December 03, 2020
Silk Road Medical Announces Changes to Board of Directors
SUNNYVALE, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the appointment of Kevin Ballinger to the company’s Board of Directors. Simultaneously, the company also
Thursday, December 03, 2020
Indus Holdings, Inc. Announces Updated Fourth Quarter Guidance
SALINAS, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Indus Holdings, Inc. ("Indus” or the “Company”) (CSE:INDS; OTCQX: INDXF), a leading, vertically-integrated, California-focused cannabis company, announces updated guidance for the fourth quarter ending December 31, 2020. All figures stated
Thursday, December 03, 2020
Catalyst Biosciences Hosting Research & Development Call on Systemic Complement Regulator Programs
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it will host a research and development call on the Company’s systemic complement regulator programs on Monday, December 14, 2020 at 12:00 pm Eastern Time. Members of
Thursday, December 03, 2020
Trident Brands Incorporated Announces New Investor Agreement to Convert Debt to Equity
All figures are in USD$ Brookfield, WI, Dec. 03, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Trident Brands, Inc (“Trident”) (OTCQB: TDNT) announced today that LiUNA Pension Fund of Central and Eastern Canada (“LPF”) through Fengate Trident LP (“Fengate”), the holder of $22.3
Thursday, December 03, 2020
Nanox Announces Successful Demonstration of the Nanox.ARC Prototype During RSNA 2020
Live demonstration featured a range of 2D and 3D imaging proceduresNEVE ILAN, Israel, Dec. 03, 2020 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announced today that the Company successfully
Thursday, December 03, 2020
Tauriga Sciences Inc. Fully Repays and Retires $88,333.00 Face Value 8.00% Convertible Debenture Issued on May 18, 2020
NEW YORK, NY, Dec. 03, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate,
Thursday, December 03, 2020
Issuance of a 4th tranche of €1.5 million of notes convertible into new shares
ISSUANCE OF A 4th TRANCHE OF €1.5 MILLION OF NOTES CONVERTIBLE INTO NEW SHARES ·DEINOVE immediately strengthens its cash position to finance the ongoing clinical trial testing DNV3837 for the treatment of severe gastrointestinal infections caused by Clostridiodes difficile DEINOVE
Thursday, December 03, 2020
OSE Immunotherapeutics and Nantes University Hospital Announce Initiation of a Phase 1/2 Clinical Trial to Evaluate CD28 Antagonist FR104 in Patients
University Hospital of Nantes will sponsor and conduct the clinical trialOSE Immunotherapeutics will provide its FR104 productPost-transplant immune response is a key therapeutic issue for patients and a new development indication for FR104 NANTES, France, Dec. 03, 2020 (GLOBE NEWSWIRE) -- OSE
Thursday, December 03, 2020
Genmab Announces that Janssen has Submitted a Biologics License Application to U.S. FDA for Amivantamab in Non-small Cell Lung Cancer
Media Release Copenhagen, Denmark, December 3, 2020 Janssen submitted a BLA to U.S. FDA for amivantamab for patients with non-small cell lung cancer with epidermal growth factor receptor Exon 20 insertion mutations First regulatory submission for a DuoBody® product candidate Genmab A/S
Thursday, December 03, 2020
Tauriga Sciences, Inc. Introduces its Product Line of CBD Infused Bath Bombs Under the Tauri-Gum Brand
The Company has Launched its Bath Bomb Product Line in 3 Distinct Fragrances: Blood Orange, Mint, and Pomegranate NEW YORK, NY, Dec. 03, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating,
Thursday, December 03, 2020
Coloplast A/S - Announcement no. 15/2020 - Articles of Association
Articles of Association for Coloplast as adopted at the annual general meeting of Coloplast A/S held today, 3 December 2020 are enclosed. For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. +45 4911 1111 Ellen
Thursday, December 03, 2020
